AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 8 - (NewsRx.com & NewsRx.net) -- A new vaccine introduced nearly 3 years ago has been shown to be effective in reducing antibiotic resistance pneumococcal disease for all ages, particularly for children under 2 years old, according to a new study presented at the 43rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago.
The study, reported by the U.S. Centers for Disease Control and Prevention, found that widespread use of a new conjugate pneumococcal vaccine has reduced antibiotic-resistant pneumococcal disease in young children, adults, and among the elderly in the United States.
More than 14,000 pneumococcal cases that occurred between 1998 and 2002 were reviewed from seven sites. These included Oregon (three counties), California (one county), Minnesota (seven counties), Georgia (twenty counties), Maryland (six counties), Connecticut (entire state) and New York (seven counties). The results demonstrated that 50% fewer invasive pneumococcal infections caused by penicillin-resistant strains occurred in 2002, after the introduction of conjugate vaccine, compared to the rate in 1999, before vaccine use. Vaccine use also reduced multi-antibiotic-resistant invasive pneumococcal disease (bacteria strains not susceptible to three or more antibiotics) by half.
"The pneumococcal conjugate vaccine, which was licensed in early 2000 in the U.S., is made to prevent disease caused by the strains that are most often resistant," said Dr. Cynthia Whitney, medical epidemiologist at the Centers for Disease Control and Prevention. "These new findings indicate that conjugate pneumococcal vaccine is an effective tool for reducing antibiotic-resistant pneumococcal disease and the spread of ...
Source: HighBeam Research, New vaccine reduces antibiotic-resistant infections and protects...